Syndax is developing axatilimab, an IgG4 humanized monoclonal antibody that binds to the ligand binding domain of the CSF-1 receptor, blocking the binding and consequent activation by both natural ligands (IL-34 and CSF-1).

  • Axatilimab in solid tumors

    CSF-1R is expressed on the surface of specific immuno-suppressive cells (e.g., tumor associated macrophages or TAMs) known to play a role in the growth, survival, and metastases of cancer. Inhibition of the CSF-1 receptor has been shown in preclinical studies to reduce the number and disrupt the activity of TAMs, generating a more immune response competent tumor microenvironment.

    This mode of action is thought to make axatilimab well suited for use in combination with multiple agent including checkpoint inhibitors, and chemotherapies. Syndax has initiated SNDX-6352-0502 to further explore this hypothesis.

  • Axatilimab in Graft versus Host Disease

    Donor derived, pro-inflammatory macrophages that are CSF-1R signaling dependent have been shown in preclinical studies to be responsible for symptoms associated with chronic Graft versus host disease (cGVHD). Syndax believes that CSF-1R blockade with axatilimab may reduce the number of these pro-inflammatory macrophages and play a meaningful role as a monotherapy agent in the treatment of chronic Graft versus host disease.


    Reproduced with permission from MacDonald, K., G. Hill, et al. (2017). “Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.” Blood, 129(1),13-21.

    Syndax has initiated SNDX-6352-0503 to further explore this hypothesis.